Elevation Oncology Ownership
| ELEV Stock | USD 0.30 0.02 7.14% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 59.1 M | Current Value 59.1 M | Avarage Shares Outstanding 28.9 M | Quarterly Volatility 16.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Elevation |
Elevation Stock Ownership Analysis
About 68.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.27. Some equities with similar Price to Book (P/B) outperform the market in the long run. Elevation Oncology recorded a loss per share of 0.78. The entity had not issued any dividends in recent years. Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. Elevation Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people. To learn more about Elevation Oncology call the company at 716 371 1125 or check out https://elevationoncology.com.Besides selling stocks to institutional investors, Elevation Oncology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Elevation Oncology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Elevation Oncology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Elevation Oncology Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Elevation Oncology are currently held by insiders. Unlike Elevation Oncology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Elevation Oncology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Elevation Oncology's insider trades
Elevation Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Elevation Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Elevation Oncology backward and forwards among themselves. Elevation Oncology's institutional investor refers to the entity that pools money to purchase Elevation Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Orbimed Advisors, Llc | 2024-12-31 | 941.3 K | Millennium Management Llc | 2024-12-31 | 815.9 K | Ikarian Capital, Llc | 2024-12-31 | 690 K | Ameriprise Financial Inc | 2024-12-31 | 444 K | Northern Trust Corp | 2024-12-31 | 432.6 K | Allostery Investments Lp | 2024-12-31 | 432.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 420.4 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 333.3 K | Citadel Advisors Llc | 2024-12-31 | 266.2 K | Tang Capital Management Llc | 2024-12-31 | 4.8 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 3.5 M |
Elevation Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elevation Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elevation Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Elevation Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Elevation Oncology Outstanding Bonds
Elevation Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Elevation Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Elevation bonds can be classified according to their maturity, which is the date when Elevation Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ELV 49 08 FEB 26 Corp BondUS28622HAA95 | View | |
| ELV 475 15 FEB 33 Corp BondUS28622HAB78 | View | |
| ELV 5125 15 FEB 53 Corp BondUS28622HAC51 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.